Kissei Pharmaceutical Co., Ltd.
KSPHFOTCHealthcare● Active
$30.28
+$4.51(+17.50%)
Market Cap$1.3B
P/E Ratio—
52W High$31.9
52W Low$25.1
Kissei Pharmaceutical Co., Ltd. (KSPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KSPHF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $98.02B | $88.33B | $75.58B | $67.49B | $65.38B |
| Cost of Revenue | $51.91B | $44.27B | $38.24B | $0.28B | $0.30B |
| Gross Profit | $46.11B | $44.06B | $37.34B | $0.22B | $0.24B |
| Gross Margin %(computed) | 47.04% | 49.89% | 49.41% | 0.33% | 0.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $10.39B | $10.36B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $49.05B | $38.29B | $33.32B | $33.50B | $32.64B |
| Operating Income | ($2.94B) | $5.77B | $4.02B | ($1.13B) | ($1.40B) |
| Operating Margin %(computed) | -3.00% | 6.54% | 5.31% | -1.67% | -2.14% |
| Interest Income | $0.15B | $0.06B | $0.02B | $0.02B | $0.04B |
| Interest Expense | $0.03B | $0.02B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | $17.00B | $15.61B | $14.45B | $13.68B | $16.51B |
| Income Tax Expense | $2.95B | $3.63B | $3.16B | $3.05B | $3.48B |
| Net Income | $13.87B | $11.96B | $11.16B | $10.53B | $12.92B |
| Net Margin %(computed) | 14.15% | 13.54% | 14.77% | 15.60% | 19.76% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $333.94 | $274.21 | $246.58 | $228.31 | $280.20 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.05B | 0.05B | 0.05B |
| EBITDA | $1.73B | $20.25B | $18.72B | $2.97B | $2.33B |
| EBITDA Margin %(computed) | 1.76% | 22.92% | 24.77% | 4.39% | 3.56% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · JPY · B
Explore more Kissei Pharmaceutical Co., Ltd. data
About Kissei Pharmaceutical Co., Ltd. (KSPHF) Income Statement
Kissei Pharmaceutical Co., Ltd. (KSPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, KSPHF reported revenue of $98.02B, gross profit of $46.11B (gross margin 47.04%), and net income of $13.87B — a net profit margin of 14.15%.
Frequently asked questions
KSPHF · 4 questionsKissei Pharmaceutical Co., Ltd. (KSPHF) reported revenue of $98.02B for 2026, up 11.0% year-over-year.
KSPHF revenueKSPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08